Effect of omeprazole and AlOH/MgOH on riociguat absorption Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Clinical efficacy of oral sildenafil therapy in the treatment of pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 347s Year: 2007
COPD and concomitant arterial hypertension: The efficacy and safety of slow-release formulation of indapamide Source: International Congress 2014 – Clinical presentations Year: 2014
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020
Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Metabolic dysfunction associated with redox imbalance in pulmonary hypertension: Effects of the prolonged sildenafil use Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Transitioning sildenafil to taladafil in PAH patients is safe Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Pharmacokinetic interactions of imatinib with bosentan and sildenafil for treatment of severe pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Combination of pentoxifylline and steroids in sarcoidosis treatment Source: Eur Respir J 2005; 26: Suppl. 49, 269s Year: 2005